No price history available.
Key financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | €m | 1,078 | 1,041 | 1,341 | 1,190 | 1,542 | 1,890 | N/A | N/A |
| Operating profit | €m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | €m | 220 | 194 | 350 | 217 | 330 | 500 | N/A | N/A |
| EPS reported | € | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | € | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | € | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | € | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | €m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | €m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | €m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | € | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | € | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Orion Oyj is a global pharmaceutical company engaged in the research, development, manufacturing, and commercialization of human and veterinary medicines, alongside active pharmaceutical ingredients (APIs). Its market reach extends across Finland, the Nordic countries, wider Europe, North America, and other international territories. The company's human health division offers both prescription drugs and self-care products. Its key prescription medications include Nubeqa for prostate cancer treatment, dexdor and Precedex for intensive care sedation, and therapies like Stalevo and Comtess/Comtan for Parkinson's disease. Other significant human products are Simdax for acute decompensated heart failure and Fareston for breast cancer. Orion also provides a comprehensive suite of Easyhaler-branded drugs, such as Salmeterol/fluticasone, Budesonide/formoterol, Formoterol, Budesonide, Beclomet, and Buventol, all designed to treat asthma and chronic obstructive pulmonary disease (COPD). In the animal health sector, Orion offers veterinary pharmaceuticals including Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie. Beyond its own product line, the company manufactures APIs for both generic and proprietary drugs and provides contract manufacturing services. Orion also acts as a distributor, marketing and selling veterinary medicines produced by other international companies. Its customer base is broad, serving various healthcare providers and professionals, including specialist and general practitioners, veterinarians, pharmacies, hospitals, healthcare centers, clinics, and laboratories, as well as direct consumers with pets. Orion Oyj fosters strategic partnerships, notably with Propeller Health to embed connectivity into its Easyhaler® portfolio for asthma and COPD, and a research collaboration and license agreement with Alligator Bioscience AB (publ) focusing on the discovery and advancement of innovative bispecific antibody cancer therapeutics. Founded in 1917, Orion Oyj is headquartered in Espoo, Finland.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
Orion Oyj is a global pharmaceutical company engaged in the research, development, manufacturing, and commercialization of human and veterinary medicines, alongside active pharmaceutical ingredients (APIs). Its market reach extends across Finland, the Nordic countries, wider Europe, North America, and other international territories. The company's human health division offers both prescription drugs and self-care products. Its key prescription medications include Nubeqa for prostate cancer treatment, dexdor and Precedex for intensive care sedation, and therapies like Stalevo and Comtess/Comtan for Parkinson's disease. Other significant human products are Simdax for acute decompensated heart failure and Fareston for breast cancer. Orion also provides a comprehensive suite of Easyhaler-branded drugs, such as Salmeterol/fluticasone, Budesonide/formoterol, Formoterol, Budesonide, Beclomet, and Buventol, all designed to treat asthma and chronic obstructive pulmonary disease (COPD). In the animal health sector, Orion offers veterinary pharmaceuticals including Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie. Beyond its own product line, the company manufactures APIs for both generic and proprietary drugs and provides contract manufacturing services. Orion also acts as a distributor, marketing and selling veterinary medicines produced by other international companies. Its customer base is broad, serving various healthcare providers and professionals, including specialist and general practitioners, veterinarians, pharmacies, hospitals, healthcare centers, clinics, and laboratories, as well as direct consumers with pets. Orion Oyj fosters strategic partnerships, notably with Propeller Health to embed connectivity into its Easyhaler® portfolio for asthma and COPD, and a research collaboration and license agreement with Alligator Bioscience AB (publ) focusing on the discovery and advancement of innovative bispecific antibody cancer therapeutics. Founded in 1917, Orion Oyj is headquartered in Espoo, Finland.